Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A

Ratings ESG MSCI

Ratings MedinCell S.A.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: MedinCell S.A.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses: MedinCell S.A.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

MedinCell S.A. SectorFrance

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

MedinCell S.A. SectorFrance

Global Valuation

-

Enterprise value

EV/Revenue

EV/EBITDA

-

EV/FCF

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

MedinCell S.A. SectorFrance

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

MedinCell S.A. SectorFrance

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

MedinCell S.A. SectorFrance

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.14B -
A
- -
896B
A
546B
BBB
372B -
AA
- -
328B
AA
283B
AAA
282B
A
275B
A
206B
A
176B
A
Average 336.45B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. Ratings MedinCell S.A.